$ASMB
Assembly Biosciences Inc

2019 Q1 Form 10-K Financial Statement

#000114420419011361 Filed on February 28, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q4 2017 Q4
Revenue $3.885M $3.735M $3.315M
YoY Change 8.98% 12.67%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.520M $8.810M $5.000M
YoY Change 67.02% 76.2% 53.85%
% of Gross Profit
Research & Development $22.70M $21.25M $10.60M
YoY Change 56.14% 100.47% 22.97%
% of Gross Profit
Depreciation & Amortization $135.0K $170.0K $100.0K
YoY Change -19.64% 70.0% 400.0%
% of Gross Profit
Operating Expenses $32.22M $30.06M $15.60M
YoY Change 59.22% 92.67% 31.42%
Operating Profit -$28.34M
YoY Change 69.96%
Interest Expense $1.280M $1.300M $330.0K
YoY Change 204.76% 293.94% -210.0%
% of Operating Profit
Other Income/Expense, Net $1.277M
YoY Change 201.89%
Pretax Income -$27.06M -$25.02M -$11.95M
YoY Change 66.53% 109.37% -1.73%
Income Tax -$7.000K $1.140M -$340.0K
% Of Pretax Income
Net Earnings -$27.05M -$26.16M -$3.007M
YoY Change 66.48% 770.0% -73.96%
Net Earnings / Revenue -696.32% -700.43% -90.71%
Basic Earnings Per Share -$1.05
Diluted Earnings Per Share -$1.05 -$1.026M -$158.3K
COMMON SHARES
Basic Shares Outstanding 25.54M 25.46M shares
Diluted Shares Outstanding 25.67B

Balance Sheet

Concept 2019 Q1 2018 Q4 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $193.5M $218.1M $119.9M
YoY Change 77.2% 81.88% 126.23%
Cash & Equivalents $29.11M $41.47M $82.03M
Short-Term Investments $164.4M $176.6M $37.90M
Other Short-Term Assets $4.300M $2.000M $900.0K
YoY Change 138.89% 122.22% 50.0%
Inventory
Prepaid Expenses
Receivables $2.987M $2.400M $2.274M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $200.8M $222.5M $123.1M
YoY Change 77.39% 80.72% 129.7%
LONG-TERM ASSETS
Property, Plant & Equipment $2.079M $557.0K $860.0K
YoY Change 197.0% -35.23% 330.0%
Goodwill $12.64M $12.64M $12.64M
YoY Change 0.0%
Intangibles $29.00M
YoY Change
Long-Term Investments $3.700M
YoY Change 37.04%
Other Assets $1.661M $3.348M $340.0K
YoY Change 884.71%
Total Long-Term Assets $58.44M $45.54M $46.19M
YoY Change 36.54% -1.39% 3.68%
TOTAL ASSETS
Total Short-Term Assets $200.8M $222.5M $123.1M
Total Long-Term Assets $58.44M $45.54M $46.19M
Total Assets $259.2M $268.0M $169.3M
YoY Change 66.18% 58.32% 72.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.400M $3.693M $2.100M
YoY Change 0.0% 75.86% -12.5%
Accrued Expenses $10.14M $9.679M $6.139M
YoY Change 120.46% 57.66% 27.9%
Deferred Revenue $5.100M $45.79M
YoY Change -88.86%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $25.21M $18.47M $13.49M
YoY Change 106.6% 36.91% 90.03%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $40.40M $35.70M $40.60M
YoY Change 2.8% -12.07%
Total Long-Term Liabilities $40.40M $38.92M $42.69M
YoY Change 2.8% -8.84% 283.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $25.21M $18.47M $13.49M
Total Long-Term Liabilities $40.40M $38.92M $42.69M
Total Liabilities $68.85M $57.39M $56.18M
YoY Change 28.44% 2.15% 208.7%
SHAREHOLDERS EQUITY
Retained Earnings -$368.8M -$341.8M -$251.0M
YoY Change 36.15%
Common Stock $26.00K $552.8M $20.00K
YoY Change 2763835.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $190.4M $210.7M $113.1M
YoY Change
Total Liabilities & Shareholders Equity $259.2M $268.0M $169.3M
YoY Change 66.18% 58.32% 72.58%

Cashflow Statement

Concept 2019 Q1 2018 Q4 2017 Q4
OPERATING ACTIVITIES
Net Income -$27.05M -$26.16M -$3.007M
YoY Change 66.48% 770.0% -73.96%
Depreciation, Depletion And Amortization $135.0K $170.0K $100.0K
YoY Change -19.64% 70.0% 400.0%
Cash From Operating Activities -$23.94M -$16.73M -$9.770M
YoY Change 54.45% 71.24% -11.5%
INVESTING ACTIVITIES
Capital Expenditures $1.488M -$210.0K -$360.0K
YoY Change 3715.38% -41.67% 227.27%
Acquisitions
YoY Change
Other Investing Activities $12.92M -$61.95M -$1.310M
YoY Change -1318.87% 4629.01% -108.3%
Cash From Investing Activities $11.44M -$62.16M -$1.670M
YoY Change -1139.55% 3622.16% -110.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $100.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 140.0K 600.0K 66.23M
YoY Change -90.63% -99.09% 44053.33%
NET CHANGE
Cash From Operating Activities -23.94M -16.73M -9.770M
Cash From Investing Activities 11.44M -62.16M -1.670M
Cash From Financing Activities 140.0K 600.0K 66.23M
Net Change In Cash -12.36M -78.29M 54.79M
YoY Change -18.15% -242.89% 1046.23%
FREE CASH FLOW
Cash From Operating Activities -$23.94M -$16.73M -$9.770M
Capital Expenditures $1.488M -$210.0K -$360.0K
Free Cash Flow -$25.43M -$16.52M -$9.410M
YoY Change 63.63% 75.56% -13.91%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
176609000
CY2017Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
37914000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2430000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2274000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1992000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
898000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
222502000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Receivable Current
OperatingLeasesFutureMinimumPaymentsReceivableCurrent
5032
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Receivable In Two Years
OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears
4537
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Receivable In Three Years
OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears
4055
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Receivable In Four Years
OperatingLeasesFutureMinimumPaymentsReceivableInFourYears
4075
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Receivable
OperatingLeasesFutureMinimumPaymentsReceivable
21794
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Receivable In Five Years
OperatingLeasesFutureMinimumPaymentsReceivableInFiveYears
4095
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2100000
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1900000
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
4200000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41471000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
82033000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
123119000
CY2018Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
0
CY2017Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
3347000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
557000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
860000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3348000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
340000
CY2018Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
29000000
CY2017Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
29000000
CY2018Q4 us-gaap Goodwill
Goodwill
12638000
CY2017Q4 us-gaap Goodwill
Goodwill
12638000
CY2018Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
45543000
CY2017Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
46185000
CY2018Q4 us-gaap Assets
Assets
268045000
CY2017Q4 us-gaap Assets
Assets
169304000
CY2018Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
3693000
CY2017Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
2124000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9679000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6139000
CY2018Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5100000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5229000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18472000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13492000
CY2018Q4 us-gaap Deferred Tax Liabilities Current
DeferredTaxLiabilitiesCurrent
3252000
CY2017Q4 us-gaap Deferred Tax Liabilities Current
DeferredTaxLiabilitiesCurrent
2136000
CY2018Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
35560000
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
40556000
CY2018Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
38920000
CY2017Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
42692000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-392000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-341787000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-251036000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
210653000
CY2018Q4 us-gaap Liabilities
Liabilities
57392000
CY2017Q4 us-gaap Liabilities
Liabilities
56184000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
25000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
20000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
552762000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
364528000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-347000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
113120000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
268045000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
169304000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
58668000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
43577000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
14023000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5726000
CY2018Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
2282000
CY2017Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
2259000
CY2018Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
11409000
CY2017Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
11064000
CY2018Q4 asmb Deferred Tax Assets Related Party Interest
DeferredTaxAssetsRelatedPartyInterest
5472000
CY2017Q4 asmb Deferred Tax Assets Related Party Interest
DeferredTaxAssetsRelatedPartyInterest
5604000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
575000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
360000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
92429000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
68590000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
87543000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
63718000
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
4886000
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
4872000
CY2018Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
8138000
CY2017Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
7008000
CY2018Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
3252000
CY2017Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
2136000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
108000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
0
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
24700000
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
28400000
CY2018 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
3700000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2017Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
4900000
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25495425
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20137974
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25495425
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20137974
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
8600000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
209200000
CY2018 us-gaap Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
The Tax Act also permits an indefinite carry forward of net operating losses generated in taxable years ending after December 31, 2017, subject to a utilization limitation of 80% of taxable income.
CY2018 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14804000
CY2017 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
9019000
CY2016 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
72741000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44225000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33093000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
34798000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17021000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12185000
CY2018 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
107539000
CY2017 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
61246000
CY2016 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
45278000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-92735000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-52227000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-45278000
CY2018 us-gaap Interest Income Other
InterestIncomeOther
3083000
CY2017 us-gaap Interest Income Other
InterestIncomeOther
983000
CY2016 us-gaap Interest Income Other
InterestIncomeOther
1539000
CY2018 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
0
CY2017 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-615000
CY2016 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-1140000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3083000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
368000
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
399000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-89652000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-51859000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-44879000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1099000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-9050000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-618000
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
45000
CY2017 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
209000
CY2016 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
221000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-90706000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42600000
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44040000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.98
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.41
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.57
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22801644
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17750380
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17226245
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
118741000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
153000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5024000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
79878000
CY2017 asmb Stock Issued During Period Value Common Stock Issued
StockIssuedDuringPeriodValueCommonStockIssued
64848000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2393000
CY2017 us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
209000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8601000
CY2018 asmb Stock Issued During Period Value Common Stock Issued
StockIssuedDuringPeriodValueCommonStockIssued
155425000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3960000
CY2018 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
408000
CY2018 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
CY2018 us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
45000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28446000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1057000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
414000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1614000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1274000
CY2018Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
176735000
CY2018Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
126000
CY2018Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
176609000
CY2017Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
41449000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
194000
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
41261000
CY2018 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
48900000
CY2017 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
33500000
CY2016 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
44300000
CY2016 us-gaap Depreciation
Depreciation
80000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
28485000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
8601000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
5024000
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Concentrations of Credit Risk</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.41in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments which potentially subject the Company to credit risk consist primarily of cash, cash equivalents and marketable securities. The Company holds these investments in highly rated financial institutions, and, by policy, limits the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5241929
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4687115
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4474160
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-90751000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-42809000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-44261000
CY2018 us-gaap Depreciation
Depreciation
643000
CY2017 us-gaap Depreciation
Depreciation
219000
CY2018 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
229000
CY2017 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
0
CY2016 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
0
CY2018 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2017 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-615000
CY2016 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-1140000
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1099000
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-9050000
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-618000
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
156000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2273000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1094000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
286000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-93000
CY2018 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
3008000
CY2017 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
84000
CY2016 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
58000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1569000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-244000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1004000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3501000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1386000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2714000
CY2018 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-5125000
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
45785000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2018 asmb Increase Decrease In Deferred Rent Noncurrent
IncreaseDecreaseInDeferredRentNoncurrent
108000
CY2017 asmb Increase Decrease In Deferred Rent Noncurrent
IncreaseDecreaseInDeferredRentNoncurrent
0
CY2016 asmb Increase Decrease In Deferred Rent Noncurrent
IncreaseDecreaseInDeferredRentNoncurrent
0
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-64958000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1860000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34882000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
340000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
865000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
147000
CY2018 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
183941000
CY2017 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
48234000
CY2016 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
7951000
CY2018 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
48884000
CY2017 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
33457000
CY2016 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
44294000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-135397000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15642000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
36196000
CY2018 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
155425000
CY2017 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
64847000
CY2016 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
CY2018 asmb Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
408000
CY2017 asmb Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
0
CY2016 asmb Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
0
CY2018 asmb Accrued Offering Cost Related To Issuance Of Common Stock
AccruedOfferingCostRelatedToIssuanceOfCommonStock
3960000
CY2017 asmb Accrued Offering Cost Related To Issuance Of Common Stock
AccruedOfferingCostRelatedToIssuanceOfCommonStock
2393000
CY2016 asmb Accrued Offering Cost Related To Issuance Of Common Stock
AccruedOfferingCostRelatedToIssuanceOfCommonStock
153000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
159793000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
67240000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
153000
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-40562000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
53458000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1467000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28575000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27108000
CY2018 asmb Share Based Compensation Arrangement By Share Based Payment Award Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate
0
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
28485000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8601000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5024000
CY2018Q4 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
21483
CY2018Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1900000
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y2M12D
CY2018Q4 asmb Common Stock Shares Subscribed Under Employee Stock Purchase Plan
CommonStockSharesSubscribedUnderEmployeeStockPurchasePlan
21483
CY2018Q4 asmb Estimated Stock Based Compensation
EstimatedStockBasedCompensation
19400000
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
700000
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2017Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
50000000
CY2018 asmb Deferred Revenue Amortization Period Over Service Tenure
DeferredRevenueAmortizationPeriodOverServiceTenure
P10Y
CY2016 us-gaap Trading Securities Unrealized Holding Gain Loss
TradingSecuritiesUnrealizedHoldingGainLoss
221000
CY2016 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
0
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.071
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.026
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.043
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.067
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.034
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.024
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.021
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.018
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.477
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0
CY2018 asmb Effective Income Tax Rate Reconciliation Change In Enacted State Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedStateTaxRate
-0.025
CY2017 asmb Effective Income Tax Rate Reconciliation Change In Enacted State Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedStateTaxRate
0.002
CY2016 asmb Effective Income Tax Rate Reconciliation Change In Enacted State Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedStateTaxRate
0.075
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.004
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.003
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.023
CY2018Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
26861000
CY2018Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3735000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.270
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.255
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.012
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.175
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.014
CY2018Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
20237000
CY2018Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
30384000
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.413
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
0.85
CY2018Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3565000
CY2018Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3218000
CY2018Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
4286000
CY2018Q4 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
30057000
CY2018Q1 us-gaap Interest Income Other
InterestIncomeOther
446000
CY2018Q2 us-gaap Interest Income Other
InterestIncomeOther
453000
CY2018Q3 us-gaap Interest Income Other
InterestIncomeOther
1116000
CY2018Q4 us-gaap Interest Income Other
InterestIncomeOther
1069000
CY2018Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-23000
CY2018Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-127000
CY2018Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-82000
CY2018Q4 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
231000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-16249000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-26806000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-21535000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-26161000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-800
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1300
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-870
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1030
CY2017Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
684000
CY2017Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2359000
CY2017Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2660000
CY2017Q4 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3315000
CY2017Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
14614000
CY2017Q2 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
15927000
CY2017Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
15110000
CY2017Q4 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
15595000
CY2017Q1 us-gaap Interest Income Other
InterestIncomeOther
136000
CY2017Q2 us-gaap Interest Income Other
InterestIncomeOther
240000
CY2017Q3 us-gaap Interest Income Other
InterestIncomeOther
241000
CY2017Q4 us-gaap Interest Income Other
InterestIncomeOther
366000
CY2017Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-137000
CY2017Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-341000
CY2017Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-99000
CY2017Q4 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-38000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-13931000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-13599000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-12272000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-3007000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-810
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-780
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-710
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-160
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5011000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4518000
CY2018Q4 asmb Accrued Clinical Trial Run Expense
AccruedClinicalTrialRunExpense
3561000
CY2017Q4 asmb Accrued Clinical Trial Run Expense
AccruedClinicalTrialRunExpense
442000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1107000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1179000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
0
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
3679000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
934000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4613000
CY2017Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1613
CY2018 asmb Warrant Maturity Term
WarrantMaturityTerm
P1Y8M12D
CY2018Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
0
CY2017Q4 asmb Initial Public Offering Value Of Shares Authorized
InitialPublicOfferingValueOfSharesAuthorized
250000000
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2018 asmb Schedule Of Collaboration Revenue Recognized With The Period
ScheduleOfCollaborationRevenueRecognizedWithThePeriod
<table cellpadding="0" cellspacing="0" style="font: 10pt &quot;times new roman&quot;, times, serif; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; border-collapse: collapse; width: 100%; border-spacing: 0px;"><tr style="vertical-align: bottom;"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; font-weight: normal; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td colspan="2" style="font-size: 10pt; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div></td><td style="font-size: 10pt; font-weight: normal; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; font-weight: normal; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td colspan="2" style="font-size: 10pt; font-weight: normal; text-align: center; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td><td style="font-size: 10pt; font-weight: normal; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt; font-weight: normal; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">($ in&#160;thousands)</div></div></td><td style="font-size: 10pt; font-weight: normal; padding-bottom: 1pt; padding-left: 0px; padding-top: 0px;">&#160;</td><td colspan="2" style="font-size: 10pt; font-weight: normal; text-align: center; border-bottom: 1pt solid black; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: normal; padding-left: 0px; padding-top: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt; font-weight: normal; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-weight:bold;display:inline;">Collaboration revenue recognized in the period from:</div></div></td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 1642px; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">Amounts included in deferred revenue at the beginning of the period</td><td style="width: 19px; font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="width: 19px; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">$</td><td style="width: 189px; font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">5,125</td><td style="width: 18px; font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">Performance obligations satisfied in previous period</td><td style="font-size: 10pt; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td><td style="font-size: 10pt; text-align: right; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#8212;</td><td style="font-size: 10pt; text-align: left; padding-left: 0px; padding-top: 0px; padding-bottom: 0px;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
CY2018 dei Document Type
DocumentType
10-K
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Entity Registrant Name
EntityRegistrantName
ASSEMBLY BIOSCIENCES, INC.
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001426800
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2018Q2 dei Entity Public Float
EntityPublicFloat
745000000
CY2018 dei Trading Symbol
TradingSymbol
ASMB
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25540757
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2018 dei Entity Small Business
EntitySmallBusiness
false
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M6D
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;times new roman&quot;, serif; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; font-size: 10pt;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates</div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.41in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of consolidated financial statements in conformity with the accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.41in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; font-size: 10pt;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Significant estimates inherent in the preparation of the accompanying consolidated financial statements include recoverability and useful lives (indefinite or finite) of intangible assets, assessment of impairment of goodwill, provisions for income taxes, amounts receivable under the collaboration agreement, and the fair value of stock options,&#160;</div>stock appreciation rights,&#160;<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">and&#160;restricted stock units (RSUs) granted to employees,&#160;directors,&#160;and consultants.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.41in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;">The Company&#8217;s estimates&#160;<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the </div>Company&#8217;s&#160;<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">estimates and could cause actual results to differ from those estimates and assumptions.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
15296
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
30.00
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
15296
CY2017Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
30.00
CY2018Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
209000000

Files In Submission

Name View Source Status
0001144204-19-011361-index-headers.html Edgar Link pending
0001144204-19-011361-index.html Edgar Link pending
0001144204-19-011361.txt Edgar Link pending
0001144204-19-011361-xbrl.zip Edgar Link pending
asmb-20181231.xml Edgar Link completed
asmb-20181231.xsd Edgar Link pending
asmb-20181231_cal.xml Edgar Link unprocessable
asmb-20181231_def.xml Edgar Link unprocessable
asmb-20181231_lab.xml Edgar Link unprocessable
asmb-20181231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv514070_10k.htm Edgar Link pending
tv514070_ex10-11.htm Edgar Link pending
tv514070_ex21-1.htm Edgar Link pending
tv514070_ex23-1.htm Edgar Link pending
tv514070_ex31-1.htm Edgar Link pending
tv514070_ex31-2.htm Edgar Link pending
tv514070_ex32-1.htm Edgar Link pending
tv514070_ex32-2.htm Edgar Link pending
tv514070_img01.jpg Edgar Link pending